Nurix is a Brisbane, California biopharmaceutical company developing cancer and inflammation drugs that remove disease-causing proteins. It last closed at $14.24 on Nov 17, down 3.33% on the day. NRIX reports earnings on Wed, Jan 27, 2027. The average 12-month price target from 6 analysts is $32.00 (+124.7% from the last close), with a high of $36.00 and a low of $20.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (6 buy, 0 hold, 0 sell).
Each firm's latest rating on NRIX in the past 90 days
Average 12-month target
$32.00
▲ 124.7% upside
Based on 6 analysts who set a price target on NRIX in the past 90 days. The average target is $32.00, with a high of $36.00 and a low of $20.00, compared with the last close of $14.24.
Low $20.00Avg $32.00High $36.00
Blue marker: last close $14.24
Highest target$36.00
Average target$32.00
Lowest target$20.00
Latest rating changes
Wells FargoTarget lowered
Nov 4Buy$25 → $20
HC Wainwright & Co.Target raised
Oct 16Buy$34 → $36
RBC CapitalTarget lowered
Oct 13Buy$36 → $35
OppenheimerMaintained
Oct 13Buy$32
Truist SecuritiesTarget lowered
Oct 13Buy$34 → $33
Date
Firm
Action
Rating
Price target
Nov 4
Wells Fargo
Target lowered
Buy
$25 → $20
Oct 16
HC Wainwright & Co.
Target raised
Buy
$34 → $36
Oct 13
RBC Capital
Target lowered
Buy
$36 → $35
Oct 13
Oppenheimer
Maintained
Buy
$32
Oct 13
Truist Securities
Target lowered
Buy
$34 → $33
Loading…
Technical Analysis
NRIX · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 46% below its 20 day and 60% below its 50 day average. It is 41% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 24), oversold. The nearest support is the Pivot S1 at $13.95, and the nearest resistance the Pivot at $14.40.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 10.1%/day
Key levels
$28.2352 week high+98.2%
$23.88100 day average+67.7%
$22.8050 day average+60.1%
$20.8120 day average+46.1%
$20.10200 day average+41.2%
$16.76Swing high (Nov 10)+17.7%
$14.70Pivot R1+3.2%
$14.40Pivot+1.1%
$14.24Last close
$13.95Pivot S1−2.0%
$12.4352 week low−12.7%
Indicators
RSI (14)
24.21
Oversold below 30
Oversold
MACD
-2.68
Below its signal line
Bearish
Stochastic
2.2
Near the bottom of its range
Oversold
ADX (14)
38.1
Trending down
Williams %R
-99.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-81.6
Oversold below −100, overbought above 100
Neutral
Rate of change
−44.9%
Change over 10 sessions
Bearish
ATR (14)
$1.44
Typical daily range, 10.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchOversold
VolatilityHigh, 19.8%/day
Key levels
$28.2352 week high+98.2%
$23.88100 day average+67.7%
$22.8050 day average+60.1%
$20.8120 day average+46.1%
$20.10200 day average+41.2%
$16.76Swing high (Nov 10)+17.7%
$14.70Pivot R1+3.2%
$14.40Pivot+1.1%
$14.24Last close
$13.95Pivot S1−2.0%
$12.4352 week low−12.7%
Indicators
RSI (14)
34.06
Weak, oversold below 30
Neutral
MACD
-0.41
Below its signal line
Bearish
Stochastic
3.3
Near the bottom of its range
Oversold
ADX (14)
24.0
Weak trend
Williams %R
-99.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-252.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−43.3%
Change over 10 sessions
Bearish
ATR (14)
$2.83
Typical daily range, 19.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for NRIX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how NRIX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow NRIX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How NRIX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NRIX is in one of them and how their past NRIX trades turned out.
Nurix is a clinical stage biopharmaceutical company based in Brisbane, California. It develops medicines based on targeted protein degradation, a approach that removes disease-causing proteins, with a focus on cancer and inflammatory conditions. Its lead candidate, bexobrutideg, is being studied in patients with relapsed or refractory chronic lymphocytic leukemia. The company also works with large drug makers, including Gilead, Sanofi and Pfizer, on collaborations that use its platform, which combines DNA encoded libraries with artificial intelligence, to find new drug candidates.